1,2-Dichloroethane → HCID 178513586, compound
Reaction equation
[C:1](O)(=[O:8])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.C(Cl)CCl.[NH:14]1[CH2:19][CH2:18][CH2:17][CH2:16][CH:15]1[CH2:20][CH2:21][O:22][C:23]1[CH:28]=[CH:27][C:26]([C:29]2[NH:33][C:32]3[CH:34]=[CH:35][C:36]([C:38]([NH2:40])=[O:39])=[CH:37][C:31]=3[N:30]=2)=[CH:25][CH:24]=1>CN(C=O)C.CN(C1C=CN=CC=1)C>[C:1]([N:14]1[CH2:19][CH2:18][CH2:17][CH2:16][CH:15]1[CH2:20][CH2:21][O:22][C:23]1[CH:24]=[CH:25][C:26]([C:29]2[NH:33][C:32]3[CH:34]=[CH:35][C:36]([C:38]([NH2:40])=[O:39])=[CH:37][C:31]=3[N:30]=2)=[CH:27][CH:28]=1)(=[O:8])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1Participants
Procedure
A solution of benzoic acid (75 mg, 0.62 mmol) and EDC (59 mg, 0.31 mmol) in DMF (1 mL) was stirred for 2 h and then was treated with 2-[4-(2-piperidin-2-yl-ethoxy)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide (75 mg, 0.21 mmol) and DMAP (65 mg, 0.53 mmol). The mixture was stirred for 18 h, and the crude material was purified by reverse phase HPLC (C18; H2O/CH3CN/0.01% TFA), providing 46 mg (66%) of the title compound. HPLC (Method C): Rt=5.15. MS (ESI+): mass calcd. for C28H28N4O3, 468.22; m/z found, 469.4 [M+H]+. 1H NMR (400 MHz, CD3OD): 8.19 (s, 1H), 8.00-7.96 (m, 3H), 7.72 (d, J=8.6 Hz, 1H), 7.36-7.25 (m, 2H), 7.25-7.10 (m, 4H), 6.95-6.90 (m, 1H), 4.20-4.07 (m, 2H), 3.92-3.90 (m, 1H), 3.48-3.43 (m, 1H), 2.45-2.35 (m, 1H), 2.12-1.81 (m, 1H), 1.81-1.30 (m, 7H).
Workup
- customthe crude material was purified by reverse phase HPLC (C18; H2O/CH3CN/0.01% TFA)
Sources & evidence
- ORD record
- ord-1e27ff44c4704aa2af1de0b64b571172
- Source dataset
- uspto-grants-2007_07
- Patent number
- US07250427B2
Reaction notes
Loading…